申请人:Tyligand Bioscience (Shanghai) Limited
公开号:EP3848365A1
公开(公告)日:2021-07-14
The present disclosure relates to a group of tropomyosin receptor kinase inhibitors comprising an amido-phenoxy-indazole structure fragment. These compounds show potent inhibitory effects on various oncogenic kinases, especially TRK, and thus can be used to treat tumors or cancers.
本公开涉及一组肌球蛋白受体激酶抑制剂,包括氨基苯氧基吲唑结构片段。这些化合物对各种致癌激酶(尤其是 TRK)具有强效抑制作用,因此可用于治疗肿瘤或癌症。